## UNITED STATES SECURITIES AND EXCHANGE COMMISSION AUGUST 3, 2009

## ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

## **Alseres Pharmaceuticals, Inc.**

## File No. 000-06533 - CF# 23864

Alseres Pharmaceuticals, Inc. submitted an application under Rule 24b-2 requesting an extension of a previous grant of confidential treatment for information it excluded from the Exhibits to a Form 10-Q filed on August 14, 2006.

Based on representations by Alseres Pharmaceuticals, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.1	through August 14, 2012
Exhibit 10.2	through August 14, 2012

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Daniel S. Greenspan Special Counsel